Fig. 7: Torin1/Verteporfin co-treatment blocks tumor growth in patient-derived xenografts.

a TNBC PDX tumors were subcutaneously transplanted into NSG mice and allowed to develop for 28 days. Mice were split into four groups (6 mice per group) with similar average tumor volume and subjected to vehicle, verteporfin (100 mg/kg), torin1 (8 mg/kg), and combination treatment (verteporfin/torin1, combo) by intraperitoneal injection for 2 weeks. Tumor growth rates from the initial measurement of individual mice are presented. Data are represented as mean±SEM and p values by two-sided unpaired t test are indicated (n = 6 mice per group). b Tumor volume of individual mice at day 37 was graphed for the treated PDX mice. Data are represented as dot plots with the middle line as the median. p values by two-sided unpaired t test are indicated (n = 6 mice per group). c Mice body weight was measured during the treatment. Changes in mice body weight during treatments are represented as mean±SEM (n = 6 mice per group). There is no significant difference between groups. d–f Representative images show that protein lysates derived from day 37 PDX tumor samples treated with vehicle, verteporfin, torin1 and combination were assessed for immunoblotting with the indicated antibodies. Quantification of the ratio of phosphor/total indicated proteins by densitometry analysis. Data are represented as mean±SEM and p values by two-sided unpaired t test are indicated (n = 6 tumor samples per group). g Representative images and quantification of PCNA positive cells in PDX tumor tissues from vehicle and drug-treated groups. Data are represented as dot plots with the middle line as the median value. p values by two-sided unpaired t test are indicated (n = 5 mice per group, 3 regions per tissue section). Scale bar is 20 µm. Source data are provided as a Source Data file.